
Should You Buy OHB Pediatrics Before the SPAC Merger Closes?
OHB Pediatrics Ltd. d/b/a Oak Hill Bio is a clinical-stage rare-disease therapeutics company going public through a merger with Research Alliance Corp III (Nasdaq: RACC). The deal is valued at about $160 million in base equity value, plus outstanding SAFEs and accrued interest, but the cash that actually reaches the company will depend on redemptions and committed financing.
